Skip to main content
SpringerLink
Log in

MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

Single nucleotide polymorphisms (SNPs) within microRNAs (miRNAs) are considered potential markers for risk and prognosis of various cancers. In the current study, we aimed to determine whether miR-608 rs4919510 affected hepatocellular carcinoma (HCC) prognosis. We genotyped rs4919510 using DNA from blood samples of 362 HCC patients receiving surgical resection of HCC tumor. Associations between rs4919510 and overall survival (OS) and demographic characteristics and clinical features were estimated using the Cox proportional hazards model. Results showed that HCC patients who carried the rs4919510 CC genotype had a significantly longer OS compared to those who carried the GG genotype (P = 0.013, hazard ratio [HR] = 0.600, 95 % confidence interval [CI] 0.402–0.897) and the CG + GG genotype (P = 0.033, HR = 0.681, 95 % CI 0.479–0.970) in univariate analysis. Similar results were obtained in multivariate analysis. Further stratification analysis indicated that rs4919510 was significantly associated with OS in patients who were satisfied with one of the following criteria: male gender, HbsAg-positive, α-fetoprotein (AFP)-positive, tumor size >5 cm, cirrhosis, solitary tumor, I + II pTNM stage, or no tumor capsule. Finally, a significantly higher frequency of rs4919510 CC genotype was observed in patients with cirrhosis (22.9 %, 55/240) than those without cirrhosis (14.0 %, 17/121) (P = 0.047). In conclusion, our results illustrated the potential role of miR-608 rs4919510 as a prognostic marker for HCC patients undergoing surgical resection of the tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58. doi:10.1038/nrgastro.2010.100.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015. doi:10.3322/caac.21262.

    Google Scholar 

  3. Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39(4):493–502. doi:10.1053/j.seminoncol.2012.05.014.

    Article  CAS  PubMed  Google Scholar 

  4. Schutte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7(2):139–49. doi:10.4254/wjh.v7.i2.139.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol: WJG. 2014;20(12):3112–24. doi:10.3748/wjg.v20.i12.3112.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):171–80. doi:10.1055/s-2005-871197.

    Article  PubMed  Google Scholar 

  7. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58. doi:10.1016/S1470-2045(12)70073-6.

    Article  CAS  PubMed  Google Scholar 

  8. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi:10.1038/nrc1997.

    Article  CAS  PubMed  Google Scholar 

  9. Bartel B. MicroRNAs directing siRNA biogenesis. Nat Struct Mol Biol. 2005;12(7):569–71. doi:10.1038/nsmb0705-569.

    Article  CAS  PubMed  Google Scholar 

  10. Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.

    PubMed  PubMed Central  Google Scholar 

  11. Tyagi N, Arora S, Deshmukh SK, Singh S, Marimuthu S, Singh AP. Exploiting nanotechnology for the development of MicroRNA-based cancer therapeutics. J Biomed Nanotechnol. 2016;12(1):28–42. doi:10.1166/jbn.2016.2172.

    Article  CAS  PubMed  Google Scholar 

  12. Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16(9):1124–31. doi:10.1093/hmg/ddm062.

    Article  CAS  PubMed  Google Scholar 

  13. Wu C, Li M, Hu C, Duan H. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014;73(2):335–41. doi:10.1007/s00280-013-2364-x.

    Article  CAS  PubMed  Google Scholar 

  14. Pardini B, Rosa F, Naccarati A, Vymetalkova V, Ye Y, Wu X, et al. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis. 2015;36(1):82–6. doi:10.1093/carcin/bgu224.

    Article  CAS  PubMed  Google Scholar 

  15. Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, et al. Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(14):3982–91. doi:10.1158/1078-0432.CCR-11-2951.

    Article  CAS  Google Scholar 

  16. Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29(11):2126–31. doi:10.1093/carcin/bgn195.

    Article  CAS  PubMed  Google Scholar 

  17. Wang R, Zhang J, Ma Y, Chen L, Guo S, Zhang X, et al. Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a large-scale population. Mol Med Rep. 2014;10(5):2736–44. doi:10.3892/mmr.2014.2536.

    CAS  PubMed  Google Scholar 

  18. Ryan BM, McClary AC, Valeri N, Robinson D, Paone A, Bowman ED, et al. rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS ONE. 2012;7(5):e36306. doi:10.1371/journal.pone.0036306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Huang AJ, Yu KD, Li J, Fan L, Shao ZM. Polymorphism rs4919510:C > G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. PLoS ONE. 2012;7(5), e35252. doi:10.1371/journal.pone.0035252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kupcinskas J, Wex T, Link A, Leja M, Bruzaite I, Steponaitiene R, et al. Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. PLoS ONE. 2014;9(1), e87467. doi:10.1371/journal.pone.0087467.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Yang PW, Huang YC, Hsieh CY, Hua KT, Huang YT, Chiang TH, et al. Association of miRNA-related genetic polymorphisms and prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21 Suppl 4:S601–9. doi:10.1245/s10434-014-3709-3.

    Article  PubMed  Google Scholar 

  22. Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, Zhu YX, et al. Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population. Endocrine. 2015;49(2):436–44. doi:10.1007/s12020-014-0467-8.

    Article  CAS  PubMed  Google Scholar 

  23. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60. doi:10.1038/sj.emboj.7600385.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402. doi:10.1038/nrc2867.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 2008;29(10):1963–6. doi:10.1093/carcin/bgn172.

    Article  CAS  PubMed  Google Scholar 

  26. Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269–74. doi:10.1073/pnas.0802682105.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, et al. Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter. 2010;15(6):524–31. doi:10.1111/j.1523-5378.2010.00806.x.

    Article  CAS  PubMed  Google Scholar 

  28. Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, et al. A functional polymorphism in pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate. 2010;70(5):467–72. doi:10.1002/pros.21080.

    CAS  PubMed  Google Scholar 

  29. Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest. 2008;118(7):2600–8. doi:10.1172/JCI34934.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Qiu F, Yang L, Zhang L, Yang X, Yang R, Fang W, et al. Polymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma. Gene. 2015;565(2):180–6. doi:10.1016/j.gene.2015.04.008.

    Article  CAS  PubMed  Google Scholar 

  31. Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol, Biomark Prev. 2012;21(1):217–27. doi:10.1158/1055-9965.EPI-11-0624.

    Article  CAS  Google Scholar 

  32. Rah H, Kim HS, Cha SH, Kim YR, Lee WS, Ko JJ, et al. Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency. Menopause. 2015;22(4):437–43. doi:10.1097/GME.0000000000000325.

    Article  PubMed  Google Scholar 

  33. Zhang Y, Schiff D, Park D, Abounader R. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS ONE. 2014;9(3), e91546. doi:10.1371/journal.pone.0091546.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, et al. Kaposi’s sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol. 2011;225(3):378–89. doi:10.1002/path.2962.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2(4):288–94. doi:10.1158/2326-6066.CIR-14-0022.

    Article  CAS  PubMed  Google Scholar 

  36. Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 2011;39(8):3026–41. doi:10.1093/nar/gkq1003.

    Article  CAS  PubMed  Google Scholar 

  37. Rutnam ZJ, Yang BB. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci. 2012;125(Pt 8):2075–85. doi:10.1242/jcs100818.

    Article  CAS  PubMed  Google Scholar 

  38. Othman N, In LL, Harikrishna JA, Hasima N. Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS ONE. 2013;8(12), e81735. doi:10.1371/journal.pone.0081735.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58–70. doi:10.3978/j.issn.2224-4778.2011.11.02.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle. 2010;9(17):3423–7.

    Article  CAS  PubMed  Google Scholar 

  41. Wang Y, van Boxel-Dezaire AHH, Cheon H, Yang J, Stark GR. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci U S A. 2013;110(42):16975–80. doi:10.1073/pnas.1315862110.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank all the patients who agreed to participate in this study. The study is supported by the National Natural Science Foundation of China (31100895, and 81472618 [to D.-K.J.]), Outstanding Young Scholar Project of Fudan University (to D.-K.J.), as well as an intramural research grant for new young teachers from Fudan University (to D.-K.J.), an intramural research grant for promotion of the scientific research ability of young teachers from Fudan University (to D.-K.J.), an intramural research grant from Huashan Hospital, Fudan University (to J.X.), an intramural research grant from Fudan-VARI Center for Genetic Epidemiology, Fudan University (to J.X.)., the Research Fund of the State Key Laboratory of Genetic Engineering, Fudan University (to L.Y. and J.X.), and the Ellrodt-Schweighauser Family Chair of Cancer Genomic Research of NorthShore University HealthSystem (J. X.).

Author information

Author notes

    Authors and Affiliations

    1. State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, 2005 Songhu Rd., Shanghai, 200438, China

      Xiao-Pin Ma, Guopeng Yu, Xubo Chen, Zhuqing Shi, Lu-Yao Zhang, Haitao Chen, Pengyin Zhang, Dong-Lin Ding, Hui-Xing Huang, Hexige Saiyin, Hongjie Yu, Jianfeng Xu, Long Yu & De-Ke Jiang

    2. Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, China

      Guopeng Yu, Zhuqing Shi, Haitao Chen, Pengyin Zhang, Hongjie Yu, Jianfeng Xu & De-Ke Jiang

    3. Center for genetic Epidemiology, School of Life Sciences, Fudan University, Shanghai, China

      Guopeng Yu, Zhuqing Shi, Haitao Chen, Pengyin Zhang, Hongjie Yu, Jianfeng Xu & De-Ke Jiang

    4. Center for Genetic Translational Medicine and Prevention, School of Public Health, Fudan University, Shanghai, China

      Guopeng Yu, Qianyi Xiao, Zhuqing Shi, Haitao Chen, Pengyin Zhang, Hongjie Yu, Jianfeng Xu & De-Ke Jiang

    5. Fudan Institute of Urology, Huashan Hospital, Fudan University, Shanghai, China

      Guopeng Yu & Jianfeng Xu

    6. Department of Urology, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

      Guopeng Yu

    7. Center for Cancer Genomics, Wake Forest University School of Medicine, Winston-Salem, NC, USA

      Guopeng Yu, Jielin Sun, S. Lilly Zheng & De-Ke Jiang

    8. Qidong Liver Cancer Institute, Qidong People’s Hospital, Qidong, Jiangsu, China

      Tao-Yang Chen, Pei-Xin Lu & Neng-Jin Wang

    9. Center for Genomic Cancer Research, NorthShore University HealthSystem, Evanston, IL, USA

      Carly Conran, S. Lilly Zheng, Jianfeng Xu & De-Ke Jiang

    10. Institute of Biomedical Science, Fudan University, Shanghai, China

      Long Yu

    11. Pritzker School of Medicine, University of Chicago, Chicago, IL, USA

      De-Ke Jiang

    Authors
    1. Xiao-Pin Ma
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Guopeng Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Xubo Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Qianyi Xiao
      View author publications

      You can also search for this author in PubMed Google Scholar

    5. Zhuqing Shi
      View author publications

      You can also search for this author in PubMed Google Scholar

    6. Lu-Yao Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    7. Haitao Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    8. Pengyin Zhang
      View author publications

      You can also search for this author in PubMed Google Scholar

    9. Dong-Lin Ding
      View author publications

      You can also search for this author in PubMed Google Scholar

    10. Hui-Xing Huang
      View author publications

      You can also search for this author in PubMed Google Scholar

    11. Hexige Saiyin
      View author publications

      You can also search for this author in PubMed Google Scholar

    12. Tao-Yang Chen
      View author publications

      You can also search for this author in PubMed Google Scholar

    13. Pei-Xin Lu
      View author publications

      You can also search for this author in PubMed Google Scholar

    14. Neng-Jin Wang
      View author publications

      You can also search for this author in PubMed Google Scholar

    15. Hongjie Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    16. Carly Conran
      View author publications

      You can also search for this author in PubMed Google Scholar

    17. Jielin Sun
      View author publications

      You can also search for this author in PubMed Google Scholar

    18. S. Lilly Zheng
      View author publications

      You can also search for this author in PubMed Google Scholar

    19. Jianfeng Xu
      View author publications

      You can also search for this author in PubMed Google Scholar

    20. Long Yu
      View author publications

      You can also search for this author in PubMed Google Scholar

    21. De-Ke Jiang
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to De-Ke Jiang.

    Ethics declarations

    Conflicts of interest

    None

    Additional information

    Xiao-Pin Ma, Guopeng Yu, Xubo Chen and Qianyi Xiao contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Ma, XP., Yu, G., Chen, X. et al. MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma. Tumor Biol. 37, 9931–9942 (2016). https://doi.org/10.1007/s13277-016-4897-1

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s13277-016-4897-1

    Keywords

    Search

    Navigation